---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-016238"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:49:33.712388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026

## Summary
- Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.
- Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.
- Cash and cash equivalents $261.3M; expected cash runway at least into 2028.
- LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.
- Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81.

## SEC filing metadata
- accession: 0001628280-26-016238
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/0001628280-26-016238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adc-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-016238
- JSON: https://secwatch.observer/filing/0001628280-26-016238.json
- Plain text: https://secwatch.observer/filing/0001628280-26-016238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.